|Bid||35.00 x 900|
|Ask||55.00 x 1400|
|Day's Range||49.77 - 50.83|
|52 Week Range||14.07 - 54.95|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.70|
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Emerson's (EMR) fiscal Q1 earnings are likely to have gained from steady demand in process and hybrid end markets. Weak global discrete manufacturing market might have been a concern.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
NEW HAVEN, Conn., Nov. 27, 2019 -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
Arvinas Inc (NASDAQ: ARVN ) shares have been on a tear ever since the company issued a platform update in late October. The Analyst Guggenheim Securities analyst Michael Schmidt initiated coverage of Arvinas ...
Arvinas, Inc. (ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup, M.D., has joined its board of directors. Dr. Smaldone Alsup, who is currently the Chief Scientific Officer and Chief Medical Officer for NDA Group, brings experience leading commercially successful product approvals and global regulatory strategies that have advanced programs through all stages of clinical development. “Laurie has a track record of leading the regulatory approval efforts for dozens of marketed products, increasing patient access to new medicines around the globe,“ said John Houston, Ph.D., President and CEO of Arvinas.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. An Arvinas Inc (NYSE: ARVN) director stepped up to the buy window this past week.
Arvinas, Inc. (ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 681,818 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arvinas.
Arvinas, Inc. (ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock. In addition, Arvinas intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $13.5 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
NEW HAVEN, Conn., Nov. 04, 2019 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,.
The S&P 500 closed at an all time high on Monday evening -- then closed at an even higher high on Wednesday -- 3,046.77. Goldman Sachs believes this rally could keep going well into 2020.A recent report from Goldman Sachs predicts that 2020 will see corporations spend nearly a half-trillion dollars on stock buybacks, mergers, and acquisitions next year. Add in buying by U.S. individual investors and foreign investors, and that buying could be pushed well beyond the $500 billion-mark, says Goldman Sachs analyst David Kostin, as investors seek to profit from "positive equity market returns," buoyed by "rising interest rates, and stabilizing US and World GDP growth."But where do you look to find those profits specifically?Using the Stock Screener at TipRanks to seek out highly rated stocks in the ever-growing healthcare sector, for which Goldman Sachs analysts expect to see double, near double, or more than double returns in the next 12 months, we've come up with three candidates for you today.Arvinas Holding (ARVN)Based in New Haven, Connecticut, cancer-fighter Arvinas is researching therapies to degrade cancer-causing proteins in diseases such as prostate cancer and breast cancer.Goldman Sachs analyst Terence Flynn upgraded Arvinas to "buy" with a $38 price target after reviewing the result of Phase 1 clinical trials of the company's ARV-110 (for prostate cancer) and ARV-471 (for breast cancer) drugs. (To watch Flynn's track record, click here)As the label "Phase 1" suggests, Flynn admits that "trials are still in the early stages," but initial safety data looks good, opening a path to proceed to evaluating "first clinical efficacy data." Flynn increases his probability of success for both ARV-110 and ARV-471 to 25% (vs. 20% prior) given the initial safety/PK data presented, which in his view "provide some incremental de-risking of the drugs."If all goes well, Flynn foresees "blockbuster potential" for both drugs, with potential peak sales of $2.9 billion and $4.7 billion, respectively -- a big improvement over the $15 million in revenue Arvinas has booked over the last 12 months.Street sentiment on this one is good as well, with three analysts initiating coverage of Arvinas over the last three months -- in addition to Goldman's upgrade. And like Goldman, all three of these other analysts rate the stock a "buy," which qualifies the stock for "strong buy" sentiment in our book. A consensus target price of $38 (in line with Goldman's own target price) implies 81% upside for the shares over the next 12 months. (See Arvinas stock analysis on TipRanks)Livongo Health (LVGO)Next up: taking a different path to healthcare, Livongo Health is a Mountain View, California, software company seeking to harness data to improve patient outcomes in the fields of hypertension treatment, diabetes care, and weight management.This one attracted the attention of Goldman Sachs analyst Robert Jones, after Livongo was awarded a contract "to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits program under one health plan covering 5.3mn lives." Beginning on January 1, 2020, and for at least nine to 12 months thereafter, Livongo will work to reduce diabetes in the federal workforce -- and receive between $20 million and $25 million for its services in 2020, and perhaps $30 million to $35 million in 2021 if all goes well.This single contract, therefore, holds the potential to grow Livongo's $113 million in trailing revenues by 22% next year -- and push Livongo stock up as high as $43 a share, in Jones' estimation, over the next 12 months.The rest of Wall Street is even more optimistic. More than half a dozen analysts have chimed in over the past couple of months, most with buy ratings, and with an average price target of $43.63. If they're right, that means Livongo stock could more than double over the next 12 months. (See Livongo stock analysis on TipRanks)Myovant Sciences (MYOV) Returning to the pharmaceutical field now, but shifting our gaze to the UK, London-based Myovant Sciences is a clinical-stage biopharmaceutical company working to develop drugs for use in women's health, with backing from Japan's Sumitomo Dainippon Pharma, which took a 46% stake in the company last quarter and is helping to move Myovant towards commercial production.Goldman Sachs analyst Paul Choi isn't looking for earnings to be much of a catalyst for the stock (because there are none). But sales revenue is anticipated to begin rolling in next year, and could quadruple to more than $153 million by 2021. Furthermore, Choi recommends the stock in anticipation of the companies signing a "definitive agreement" of their partnership, assigning Myovant stock a "buy" rating and an $18 price target. (To watch Choi's track record, click here)Wall Street as a whole is similarly bullish, with three "buy" ratings filed in the last two months (including Goldman's), making the stock a "Strong Buy" according to TipRanks. With Street analysts positing an average $22 average price target, Myovant shows the most profit potential of all on today's list -- 325% to be exact. (See Myovant stock analysis on TipRanks)
Is Arvinas, Inc. (NASDAQ:ARVN) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks historically […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 22) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
Arvinas, Inc., (ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced a platform data update that includes initial safety, tolerability, and pharmacokinetic data from the company’s ongoing Phase 1 clinical trials of ARV-110 and ARV-471. The data, which show dose-proportional exposures of ARV-110 and that both ARV-110 and ARV-471 have been well tolerated, will be presented by Ian Taylor, Ph.D., Chief Scientific Officer at Arvinas, at the 2nd Targeted Protein Degradation Summit in Boston, MA. “This is the first look at clinical data from our PROTAC® platform and is an exciting milestone for both Arvinas and for the field of targeted protein degradation.
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 TrialsNeuroscience Presentation to Include Data from Preclinical Tau.
Arvinas, Inc. (ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new members are Tomasz M. Beer, M.D., F.A.C.P., Adam L. Boxer, M.D., Ph.D., Sara Courtneidge, Ph.D., Lennart Mucke, M.D., Benjamin G. Neel, M.D., Ph.D., and Lillian L. Siu, M.D. “Over the next year we will share our first-in-human data from a clinical trial of a targeted protein degrader and continue to progress our neurodegeneration PROTAC® programs.
Fresh off its Monsanto deal, German agtech giant Bayer is funneling $55 million into a new startup with a big Triangle touchpoint.
Bayer and Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced they have finalized the terms of their agreement to jointly launch a new company, Oerth Bio (pronounced “Earth”), and named John Dombrosky as its chief executive officer. John Dombrosky and others from the Oerth Bio team will be presenting an overview of the company at Bayer’s Future of Farming Dialogue meeting being held today in Monheim.
The company has already demonstrated ARV-110’s anti-tumor activity in preclinical prostate cancer models that are insensitive or resistant to second-generation AR antagonists, the analyst said. The initial data from the candidate’s clinical trials in metastatic castration-resistant prostate cancer patients is expected in the fourth quarter this year.